Back to top
more

BIOVERATIV INC (BIVV)

(Real Time Quote from BATS)

$104.98 USD

104.98
NA

0.00 (0.00%)

Updated Mar 8, 2018 08:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Clovis Oncology (CLVS) Soars: Stock Adds 6.6% in Session

Clovis Oncology (CLVS) was a big mover last session, as the company saw its shares rise nearly 7% on the day.

    Here's Why You Must Add Hologic (HOLX) to Your Portfolio Now

    Hologic's (HOLX) GYN Surgical business boasts huge future prospects. Also, the recent commercial launch of MyoSure MANUAL device in the United States looks promising.

      Orthofix (OFIX) Earnings & Revenues Beat Estimates in Q4

      Orthofix (OFIX) launches 20 products in 2018 and even schedules 17 more to be unveiled this year. Also, a strong full-year guidance bodes well for the company's better prospects.

        Achillion Pharmaceuticals (ACHN) Soars: Stock Adds 15.4% in Session

        Achillion Pharmaceuticals (ACHN) was a big mover last session, as the company saw its shares rise more than 15% on the day.

          Masimo's SpHb Hemoglobin Monitoring Study Results Positive

          New study proves that Masimo's (MASI) noninvasive SpHb is more efficient in hemoglobin monitoring when compared to invasive LabHb.

            Here's Why You Must Add Haemonetics (HAE) to Your Portfolio

            Haemonetics (HAE) delivers strong plasma revenues, driven by a robust performance in disposables and software in the United States. Also, the market seems upbeat about this new PCS platform.

              Varian (VAR) Acquires Evinance to Boost Oncology Segment

              Varian Medical Systems (VAR) acquires Evinance to improve cancer care through CDS software. The company also expects to gain from flagship ARIA's recent certification.

                Sangamo Therapeutics (SGMO) Looks Good: Stock Adds 14.4% in Session

                Sangamo Therapeutics (SGMO) shares rose more than 14% in the last trading session, amid huge volumes.

                  Express Scripts, Walgreens Tie Up to Cut Specialty Drug Price

                  Express Scripts (ESRX) expands group purchasing effort with Walgreens Boots Alliance to simplify supply chains and make specialty drugs affordable.

                    Cerner Partnering With Surescripts to Revamp EHR Platform

                    Cerner (CERN) will introduce Surescripts' Real-Time Prescription Benefit functionality into "Cerner Millennium's" EHR platform to help clients curtail escalating healthcare costs.

                      Hologic Banks on Diagnostics, GYN Surgical Prospects Bright

                      Hologic (HOLX) stays upbeat about GYN Surgical on the recent commercial launch of MyoSure MANUAL device in the United States.

                        Pharmacy Services Aid CVS Health, Aetna Deal an Upside Too

                        CVS Health (CVS) is likely to earn $750 million from near-term synergies after the completion of Aetna acquisition deal.

                          Inogen (INGN) Gains on Diverse Product Line, Competition Rife

                          Inogen (INGN) rides on POC growth. Existing market challenges likely to mar prospects.

                            Exactech (EXAC) Gets Acquired by TPG Capital, Goes Private

                            TPG Capital acquires Exactech (EXAC) with a view to cash in on its resources and gain a foothold in the orthopedics market.

                              Abiomed's Extended FDA Nod for Impella Boosts Women Health

                              Abiomed (ABMD) boosts cardiomyopathy treatment with the extended FDA nod for Impella. This parallelly bolsters women's cardiac treatment.

                                AmerisourceBergen (ABC) Gains on World Courier Unit Strength

                                AmerisourceBergen's (ABC) World Courier business gets GDP designation.

                                  Sanofi (SNY) Q4 Earnings Lag on Weak Diabetes/Vaccines Sales

                                  Sanofi misses estimates for both earnings and sales in the fourth quarter hurt by continued weakness in the Diabetes franchise and lower vaccine sales. Sanofi looks to return to growth in 2018.

                                    4 Reasons Why You Should Buy Accuray (ARAY) Stock Right Now

                                    Accuray (ARAY) rides high on its Radixact platform and latest software overhaul.

                                      Sanofi on a Buyout Spree This Month, to Buy Ablynx for $4.8B

                                      Sanofi (SNY) to acquire Ablynx for EUR 3.9 billion to expand its late stage pipeline and strengthen rare blood disorder growth platform.

                                        Masimo (MASI) Receives FDA Approval for SedLine, Shares Up

                                        Masimo (MASI) to overhaul neurological diagnoses with its next generation SedLine brain function monitoring.

                                          Iovance Biotherapeutics (IOVA) in Focus: Stock Moves 5.1% Higher

                                          Iovance Biotherapeutics (IOVA) shares rose more than 5% in the last trading session, amid huge volumes.

                                            Adverum Biotechnologies (ADVM) Jumps: Stock Rises 7.9%

                                            Adverum Biotechnologies (ADVM) was a big mover last session, as the company saw its shares nearly 8% on the day amid huge volumes.

                                              Editas Medicine (EDIT) Surges: Stock Moves 13.2% Higher

                                              Editas Medicine (EDIT) was a big mover last session, as the company saw its shares rise more than 13% on the day amid huge volumes.

                                                Quality Systems (QSII) Q3 Earnings in Line, Revenues Beat

                                                Quality Systems (QSII) benefits from solid bookings and acquisitions in Q3.

                                                  AngioDynamics Receives FDA Nod, to Treat Pancreatic Cancer

                                                  AngioDynamics (ANGO) gets flagship NanoKnife designated with EAP.